New blood test to 'revolutionise' NHS cancer treatment
- The NHS announced a rollout of a liquid biopsy blood test in 2025 to speed up targeted treatment for lung and breast cancer patients in England.
- This rollout follows a 176-hospital pilot where about 10,000 lung cancer patients used liquid biopsies to detect tumour DNA mutations faster than tissue biopsies.
- The test identifies genetic variants to help tailor therapies, potentially benefiting 15,000 patients annually and saving the NHS up to £11 million per year in lung cancer care.
- Professor Peter Johnson highlighted that liquid biopsies are transforming personalised cancer treatment, and expressed his enthusiasm about the NHS now being able to broaden access to this innovative test.
- The expansion could reduce delays in treatment decisions by 16 days on average and may extend to other cancers like pancreatic, improving care accessibility and precision.
64 Articles
64 Articles
NHS to Roll out ‘Revolutionary’ Blood Test for Lung Cancer
People with lung cancer will be offered a new blood test designed to speed up access to targeted treatments and avoid unnecessary biopsies, officials have announced. About 15,000 patients a year are expected to benefit from the world-first rollout, according to NHS England. The test, known as a liquid biopsy, uses a blood sample to look for tiny fragments of tumour DNA and detect mutations. This allows patients to access therapies tailored to th…
'Revolutionary' new NHS cancer test will see thousands get quicker treatment - The Mirror
The new "liquid biopsy" test searches for tiny fragments of DNA that are shed by tumours into the bloodstream - it can deliver a specific diagnosis up to two weeks earlier than usual tissue biopsy methods
Coverage Details
Bias Distribution
- 43% of the sources are Center
To view factuality data please Upgrade to Premium